Gyre Therapeutics Inc. (GYRE) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Gyre Therapeutics Inc. stock (GYRE) is currently trading at $7.18. Gyre Therapeutics Inc. PE ratio is 336.00. Gyre Therapeutics Inc. PS ratio (Price-to-Sales) is 5.55. Analyst consensus price target for GYRE is $18.67. WallStSmart rates GYRE as Sell.
- GYRE PE ratio analysis and historical PE chart
- GYRE PS ratio (Price-to-Sales) history and trend
- GYRE intrinsic value — DCF, Graham Number, EPV models
- GYRE stock price prediction 2025 2026 2027 2028 2029 2030
- GYRE fair value vs current price
- GYRE insider transactions and insider buying
- Is GYRE undervalued or overvalued?
- Gyre Therapeutics Inc. financial analysis — revenue, earnings, cash flow
- GYRE Piotroski F-Score and Altman Z-Score
- GYRE analyst price target and Smart Rating
Gyre Therapeutics Inc.
📊 No data available
Try selecting a different time range
GYRE Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Gyre Therapeutics Inc. (GYRE)
GYRE trades 735% above its Graham fair value of $0.94, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Gyre Therapeutics Inc. (GYRE) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth, eps growth. Concerns around return on equity and operating margin. Mixed signals suggest waiting for clearer direction before acting.
Gyre Therapeutics Inc. (GYRE) Key Strengths (2)
Revenue surging 33.40% year-over-year
Earnings per share surging 166.20% year-over-year
Supporting Valuation Data
Gyre Therapeutics Inc. (GYRE) Areas to Watch (7)
Near-zero operating margins, business under pressure
Very expensive at 5.8x book value
Very thin margins, barely profitable
Very low institutional interest at 3.69%
Low profitability relative to shareholder equity
Premium valuation at 5.5x annual revenue
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Gyre Therapeutics Inc. (GYRE) Detailed Analysis Report
Overall Assessment
This company scores 39/100 in our Smart Analysis, earning a F grade. Out of 9 metrics analyzed, 2 register as strengths (avg 10.0/10) while 7 fall into concern territory (avg 2.7/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, EPS Growth. Growth metrics are encouraging with Revenue Growth at 33.40%, EPS Growth at 166.20%.
The Bear Case
The primary concerns are Operating Margin, Price/Book, Profit Margin. Some valuation metrics including Price/Sales (5.55), Price/Book (5.77) suggest expensive pricing. Profitability pressure is visible in Return on Equity at 8.21%, Operating Margin at 0.32%, Profit Margin at 4.31%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Operating Margin improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 8.21% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 33.40% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Operating Margin and Price/Book are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
GYRE Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
GYRE's Price-to-Sales ratio of 5.55x trades at a deep discount to its historical average of 279.71x (9th percentile). The current valuation is 100% below its historical high of 3293.19x set in Dec 2017, and 2821% above its historical low of 0.19x in Mar 2023. Over the past 12 months, the PS ratio has compressed from ~8.3x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Gyre Therapeutics Inc. (GYRE) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Gyre Therapeutics Inc. is a strong growth company balancing expansion with improving profitability. Revenue reached 117M with 33% growth year-over-year. Profit margins are strong at 431.0%, reflecting pricing power and operational efficiency.
Key Findings
Revenue growing at 33% YoY, reaching 117M. This pace significantly outperforms most BIOTECHNOLOGY peers.
ROE of 821.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Free cash flow is -6M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Gyre Therapeutics Inc. maintain 33%+ revenue growth, or will competition slow it down?
Valuation compression risk at a P/E of 336.0x. Any growth miss could trigger a sharp correction.
Volatility is elevated with a beta of 6.92, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Gyre Therapeutics Inc..
Bottom Line
Gyre Therapeutics Inc. offers an attractive blend of growth (33% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Gyre Therapeutics Inc.(GYRE)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Gyre Therapeutics Inc. is a biopharmaceutical innovator focused on developing groundbreaking therapies for rare and complex diseases. Leveraging a proprietary platform, the company accelerates the discovery and commercialization of precision treatments tailored to address significant unmet medical needs. With a strong commitment to scientific rigor and patient-centered outcomes, Gyre is strategically positioned to advance its pipeline in gene therapy and precision medicine. Their dedication to research excellence and strategic partnerships highlights their potential for substantial growth in an increasingly competitive biopharmaceutical sector.